Hypercholesterolemia and progressive kidney disease: The role of macrophages and macrophage-derived products

Contributions to Nephrology

Volumn 120, Issue , 1997, Pages 197-209

  Ricardo, Sharon D ^a   Van Goor, Harry ^b   Diamond, Jonathan R ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; LOW DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; FOCAL GLOMERULOSCLEROSIS; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; MACROPHAGE; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ALPHA-MACROGLOBULINS; ANIMALS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; HYPERCHOLESTEROLEMIA; KIDNEY DISEASES; LIPOPROTEINS, LDL; MACROPHAGES; PROTEASE INHIBITORS; REACTIVE OXYGEN SPECIES; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030624595     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000059838     Document Type: Article

References (51)

1. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int 1988;33:917-924.
2. Keane WF, Kasiske BL, O'Donnell MP: Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis. Am J Nephrol 1988;8:261-271.
3. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988;318:1657-1666.
4. Diamond JR: The role of cholesterol in glomerular injury; in Keane WF, Stein JH (eds): Contemporary Issues in Nephrology: Lipids and Renal Disease. New York, Churchill Livingstone, 1991, vol 24, pp 109-126.
5. Steinberg D: Lipoproteins and the pathogenesis of atherosclerosis. Circulation 1987;76:508-514.
6. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924.
7. Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-2998.
8. Lee HS, Lee JS, Koh HI, Ko KW: Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991;36:67-75.
9. Joles JA, van Goor H, Braam B, Willekes-Koolschijn N, Jansen EH, van Tol A, Koomans HA: Proteinuria, lipoproteins and renal apolipoprotein deposits in uninephrectomized female analbuminemic rats. Kidney Int 1995;47:442-453.
10. van Goor H, van der Horst ML, Atmosoerodjo J, Joles JA, van Tol A, Grond J: Renal apolipoproteins in nephrotic rats. Am J Pathol 1993;142:1804-1812.
11. Fernando RL, Varghese Z, Moorhead JF: Oxidation of low-density lipoproteins by rat mesangial cells and the interaction of oxidized low-density lipoproteins with rat mesangial cells in vitro. Nephrol Dial Transplant 1993;8:512-518.
12. Lee HS, Koh HI: Visualization of binding and uptake of oxidized low density lipoproteins by cultured mesangial cells. Lab Invest 1994;71:200-208.
13. Satriano JA, Hora K, Shan Z, Stanley ER, Mori T, Schlondorff D: Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-γ, tumor necrosis factor-α, IgG aggregates, and cAMP in mouse mesangial cells. J Immunol 1993;150:1971-1978.
14. Rovin BH, Tan LC: LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993;43:218-225.
15. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 1995;26:152-161.
16. Pesek-Diamond I, Ding G, Frye J, Diamond JR: Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 1992;263:F776-F783.
17. van Goor H, Fidler V, Weening JJ, Grond J: Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation: Evidence for involvement of macrophages and lipids. Lab Invest 1991;64:754-765.
18. Magil AB, Cohen AH: Monocytes and focal glomerulosclerosis. Lab Invest 1989;61:404-409.
19. Diamond JR, Pesek I, Ruggieri S, Karnovsky MJ: Essential fatty acid deficiency during acute puromycin nephrosis ameliorates later renal injury. Am J Physiol 1989;257:F798-F807.
20. Diamond JR, Pesek I, McCarter MD, Karnovsky MJ: Altered functional characteristics of rat macrophages during nephrosis: Synergistic effects of hypercholesterolemia. Am J Pathol 1989;135:711-718.
21. Schreiner GF, Rovin B, Lefkowith JB: The antiinflammatory effects of essential fatty acid deficiency in experimental glomerulonephritis: The modulation of macrophage migration and eicosanoid metabolism. J Immunol 1989;143:3192-3199.
22. Schreiner GF: The role of the macrophage in glomerular injury. Semin Nephrol 1991;11:268-275.
23. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF: Renal injury of diet-induced bypercholesterolemia in rats. Kidney Int 1990;37:880-891.
24. Diamond JR, Pesek-Diamond I: Sublethal X-irradiation during acute puromycin nephrosis prevents late renal injury: Role of macrophages. Am J Physiol 1991;260:F779-F786.
25. Schonholzer KW, Waldron M, Magil AB: Intraglomerular foam cells and human focal glomerulosclerosis. Nephron 1992;62:130-136.
26. Kees Folts D, Diamond JR: Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome. Am J Nephrol 1993;13:365-375.
27. Parthasarathy S, Printz DJ, Boyd D, Joy J, Steinberg D: Macrophage oxidation of low density lipoproteins generates a modified form recognized by the scavenger receptor. Arteriosclerosis 1986;6:505-510.
28. Boyce NW, Tipping PG, Holdsworth SR: Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. Kidney Int 1989;35:778-782.
29. Cathcart MK, McNally AK, Morel DW, Chisolm GM: Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein to a cytotoxin. J Immunol 1989;142:1963-1969.
30. Radeke HH, Meier B, Topley N, Floge J, Habermehl GG, Resch K: Interleukin 1-α and tumor necrosis factor-α induce oxygen radical production in mesangial cells. Kidney Int 1990;37:767-775.
31. Steinberg D: Antioxidants in the prevention of human atherosclerosis. Circulation 1992;85:2338-2344.
32. Fruebis J, Steinberg D, Dresel HA, Carew TE: A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor deficient rabbits. J Clin Invest 1994;94:392-398.
33. Bjorkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L, Henriksson P: The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 1991;11:15-22.
34. Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA, Chao YS: Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol fed rabbits by the antioxidant N,N′-diphenyl-phenylenediamine. J Clin Invest 1992;89:1885-1891.
35. Ricardo SD, Diamond JR: Reactive oxygen species (ROS) and antioxidant expression in experimental hydronephrosis. J Am Soc Nephrol 1995;6:401.
36. Ohyama K, Seyer JM, Raghow R, Kamg AH: A factor from damaged rat kidney stimulates collagen biosynthesis by mesangial cells. Biochim Biophys Acta 1990;1053:173-178.
37. Shan ZT, Satriano J, Silbiger S, Schlondorff D: Intracellular glutathione influences collagen generation by mesangial cells. Kidney Int 1994;46:288-295.
38. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
39. Ding G, Pesek-Diamond I, Diamond JR: Cholesterol, macrophages, and gene expression of TGF-β1 and fibronectin during nephrosis. Am J Physiol 1993;264:F577-F584.
40. Struder RK, Craven PA, DeRubertis FR: Low-density lipoprotein stimulation of mesangial cell fibronectin synthesis: Role of protein kinase C and transforming growth factor-β. J Lab Clin Med 1995;125:86-95.
41. Ding G, van Goor H, Orlowski JM, Diamond JR: Expression of transforming growth factor (TGF)-β and α-smooth muscle actin (α-SMA) in human glomerular epithelial cells (hGECs). Kidney Int, in press.
42. Diamond JR, van Goor H, Engelmyer E: Myofibroblast transformation in experimental hydronephrosis. Am J Pathol 1995;145:121-129.
43. Chu CT, Pizzo SV: α2-Macroglobulin, complement, and biologic defense: Antigens, growth factors, microbial proteases, and receptor ligation. Lab Invest 1994;71:792-912.
44. Zheng G, Bachinsky DR, Stqamenkovic I, Strickland DK, Brown D, Andres G, McCluskey RT: Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/α2MR, and the receptor-associated protein (RAP). J Histochem Cytochem 1994;42:531-542.
45. van Goor H, Joles JA, van der Horst MLC, Koomans H, Kaysen GA: α2-Macroglobulin (α2M) and transforming growth factor (TGF)-β in nephrotic rats. J Am Soc Nephrol 1995;6:1033.
46. Lonberg-Holm K, Reed DL, McCarter MD, Karnovsky MJ: Altered functional characteristics of rat macrophages during nephrosis: Synergistics effects of hypercholesterolemia. Am J Pathol 1989;135:711-718.
47. Wooley DE, Roberts DR, Evanson JM: Small molecular weight b1 serum protein which specifically inhibits human collagenase. Nature 1976;261:325-327.
48. Cawston TE, Mercer E: Preferential binding of collagenase to a a2-macroglobulin in the presence of the tissue inhibitor of metalloproteinases. FEBS Lett 1986;209:2-12.
49. van Goor H, Kaysen G: Inhibition of extracellular matrix degradation in glomerular and interstitial fibrosis. Nephrol Dial Transplant, in press.
50. Marti HP, Lee L, Kashgarian M, Lovett DH: Transforming growth factor-β1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol 1994;144:82-94.
51. Salo T, Makela M, Kylmaniem IM, Autio-Harmainen H, Larjava H: Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 1994;80:176-182.